Pharmaceutical News

RSS

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

The bivalent oral polio vaccine (bOPV) was found to induce a significantly higher immune response than the existing trivalent oral polio vaccine (tOPV), according to a study published on Tuesday in the journal Lancet, Reuters reports.

27 Oct 2010

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Study finds anti-obesity drug reduces brain’s response to appetizing foods

Scientists have revealed that an anti-obesity drug changes the way the brain responds to appetising, high-calorie foods in obese individuals. This insight may aid the development of new anti-obesity drugs which reduce the activity in the regions of the brain stimulated by the sight of tasty foods.

27 Oct 2010

Jamieson releases flu-fighting formula with echinacea

Jamieson Laboratories, Canada's largest manufacturer of advanced natural-health products, announced the release of FluShield™, a clinically proven flu-fighting formula that is made with a patented, next-generation echinacea extract known as LPx3.

27 Oct 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Glaxo to pay $750 million in defective drug settlement

GlaxoSmithKline Plc, one of the world’s largest pharmaceutical companies, has agreed to pay $750 million to settle a U.S. government false-claims lawsuit over the sale of defective drugs. The lawsuit first filed in 2004 by Cheryl D. Eckard, a former global quality assurance manager for the London-based company came to a settlement finally. Eckard, 51, said, “This is not something I wanted to do, but because of patient safety it was necessary.” Being the one to bring this to notice she would receive $96 million from the settlement money. She had warned the company earlier but was fired because of her efforts.

26 Oct 2010

Strativa enters amended agreement with Sobi for Nascobal Vitamin B12 Nasal Spray

Strativa Pharmaceuticals today announced that it has entered into an amended and restated license and supply agreement with Swedish Orphan Biovitrum (Sobi) covering the European development and commercialization rights of Strativa's Nascobal (cyanocobalamin) Vitamin B12 Nasal Spray. Strativa acquired the worldwide rights to Nascobal from QOL Medical, LLC in March 2009, which included a pre-existing agreement with Sobi.

26 Oct 2010

Shire receives Paragraph IV Notice Letter from Watson for INTUNIV tablet

Shire plc , the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 4 mg guanfacine hydrochloride extended release tablet, INTUNIV.

26 Oct 2010

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

"India believes a row with the European Union over seizures of generic drugs will be settled without litigation, Trade Minister Anand Sharma said on Wednesday," Reuters reports (Lynn, 10/20).

26 Oct 2010

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

From Vitabiotics Ltd. 26 Oct 2010

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

PAREXEL Consulting, a business unit of PAREXEL International and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the New Normal Emerging FDA Review Outcome Trends for New Drugs.

From Parexel 26 Oct 2010

Independent drugstores expand and generate strong profits despite worst economy

Amidst the worst economy of the past seventy years, independent drugstores are expanding and generating strong profits, according to a new economic report by the National Community Pharmacists Association (NCPA). The report shows that there are almost 400 more independent drugstores than last year and that profits (3.2%) are three times greater than the rate of U.S. inflation (1.1%).

26 Oct 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Admissions for medication, drug-related conditions increase by 117% among Americans aged 45 and older

The number of hospital admissions among Americans ages 45 and older for medication and drug-related conditions doubled between 1997 and 2008, according to a new report released today by HHS' Agency for Healthcare Research and Quality. Medication and drug-related conditions include effects of both prescription and over-the-counter medications as well as illicit drugs.

26 Oct 2010

Omeros to develop new drugs for major diseases

The Life Sciences Discovery Fund (LSDF) today announced a $5 million grant to Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and commercialize new drugs to treat a variety of major diseases. With successful generation of proceeds through partnering and the sales of drugs in the marketplace, an additional outcome of the grant would be establishment of a new non-profit initiative to advance the life sciences sector and improve health and economic growth in Washington state.

26 Oct 2010

Pharmacopeias of US and Kazakhstan sign accord

With the mutual goal of improving the quality of pharmaceuticals worldwide, the United States Pharmacopeial Convention (USP) and the Republican State Enterprise (RSE) National Centre for Expertise of Drugs, Medical Products and Equipment ("the Centre") of the Ministry of Health of the Republic of Kazakhstan have entered into an agreement to share standards for the quality, purity, strength and identity of medicines.

26 Oct 2010

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability profile was comparable to that of Sutent.

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Breast Cancer Awareness month spotlights the increasingly high incidence of breast cancer, and also brings attention to the question, "what is being done to speed and ease recovery?"

26 Oct 2010

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Savient Pharmaceuticals, Inc. announced that its previously announced process to identify, following the approval of KRYSTEXXA by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

26 Oct 2010

Pharmaceutical News

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Study finds anti-obesity drug reduces brain’s response to appetizing foods

Jamieson releases flu-fighting formula with echinacea

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Glaxo to pay $750 million in defective drug settlement

Strativa enters amended agreement with Sobi for Nascobal Vitamin B12 Nasal Spray

Shire receives Paragraph IV Notice Letter from Watson for INTUNIV tablet

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

Independent drugstores expand and generate strong profits despite worst economy

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Admissions for medication, drug-related conditions increase by 117% among Americans aged 45 and older

Omeros to develop new drugs for major diseases

Pharmacopeias of US and Kazakhstan sign accord

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

IDC grants MedImmune global rights to GLA adjuvant

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News